A Cure for thalassemia major – from allogeneichematopoietic stem cell transplantation togene therapy

In 2014 we introduced anti-thymocyte globulin (ATG) to the graft-versus-host disease (GvHD) prophylaxis regimen in allogeneic stem cell transplantation (Allo-HSCT) with peripheral

con fi dence interval [95%] for Brief Sexual Function Inventory (BSFI) problem* among male lymphoma survivors treated with high-dose chemotherapy with autologous

26,27 Supporting evidence for our use of daratumumab in a patient with pure red-cell aplasia after alloge- neic stem-cell transplantation with a major ABO mismatch came from a

Results of a phase 1 study of quizartinib (AC220) as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic cell

Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.. Jo S

Allo- HSCT, allogeneic haematopoietic stem- cell transplantation; 2D, two dimensions; E/e', ratio of early- diastolic velocity to mean early- diastolic myocardial velocity;